Core Viewpoint - AnaptysBio has filed a partial motion to dismiss a claim from GSK's oncology unit regarding a breach of contract related to royalties from the cancer drug Jemperli [1] Group 1 - AnaptysBio is currently involved in a legal dispute with GSK's oncology unit [1] - The dispute centers around allegations that AnaptysBio breached their contract [1] - The claim involves royalties tied to the sales of the cancer drug Jemperli [1]